[Pharmacological property, mechanism of action and clinical study results of Pabinafusp Alfa (Genetical Recombination) (IZCARGO<sup>®</sup> I.V. Infusion 10âmg) as the therapeutic for Mucopolysaccharidosis type-II (Hunter syndrome)].

Yamamoto, Ryuji; Kawashima, Satoshi

[Pharmacological property, mechanism of action and clinical study results of Pabinafusp Alfa (Genetical Recombination) (IZCARGO^® I.V. Infusion 10âmg) as the therapeutic for Mucopolysaccharidosis type-II (Hunter syndrome)].

Yamamoto, Ryuji; Kawashima, Satoshi.

Afiliação

Yamamoto R; Pharmacology & Toxicology Unit, Drug Discovery Research Institute, Research Division, JCR Pharmaceuticals Co., Ltd.
Kawashima S; Planning Department, Development Division, JCR Pharmaceuticals Co., Ltd.

Nihon Yakurigaku Zasshi ; 157(1): 62-75, 2022.

Article em Ja | MEDLINE | ID: mdl-34980815

Assuntos

Iduronato Sulfatase; Mucopolissacaridose II; Animais; Modelos Animais de Doenças; Terapia de Reposição de Enzimas; Humanos; Iduronato Sulfatase/genética; Iduronato Sulfatase/uso terapêutico; Camundongos; Mucopolissacaridose II/tratamento farmacológico; Mucopolissacaridose II/genética; Recombinação Genética

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Mucopolissacaridose II / Iduronato Sulfatase Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: Ja Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google